What is Eloctate?
Eloctate is a brand of human recombinant coagulation factor VIII used to treat hemophilia A (congenital factor VIII deficiency). It is designed to help your blood clot by replacing the missing factor VIII. [1]
How does Eloctate work in hemophilia A?
Hemophilia A causes low factor VIII activity, leading to bleeding that can be difficult to control. Eloctate provides factor VIII to restore clotting ability. [1]
What is Eloctate used for?
Eloctate is used for people with hemophilia A, including for treatment of bleeding episodes and to help prevent bleeding (depending on the prescribed regimen). [1]
Is Eloctate “long-acting”?
Eloctate is commonly described as a long-acting (extended half-life) factor VIII product, which is intended to reduce how often factor VIII infusions are needed compared with older, shorter-acting products. [1]
What do people usually ask about dosing and timing?
Dosing of factor VIII products is individualized based on:
- the person’s factor VIII levels and bleeding pattern
- whether the goal is treatment of a current bleed or prevention
- the type and severity of the bleeding event (if treating a bleed)
Your prescriber sets the exact dose and schedule for you. [1]
What side effects or safety concerns come up with factor VIII products?
Common safety concerns for clotting-factor therapies generally include:
- infusion-related reactions
- development of inhibitors (antibodies) against factor VIII, which can reduce effectiveness
The specific safety profile and monitoring instructions are provided with the prescribing information for Eloctate. [1]
Who makes Eloctate and where is it available?
Eloctate is marketed by Bioverativ (a Sanofi company at the time referenced in available labeling materials). [1]
Sources
- Eloctate (Antihemophilic Factor [Recombinant], Fc Fusion Protein) prescribing information / product information